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Neuroblastoma (NB) is the most common extracranial solid tumor of early childhood; it ac-
counts for approximately 8–10% of all childhood cancers and is the most common cancer in
children in the first year of life. Patients in the high-risk group have a poor prognosis, with re-
lapses being common and often refractory to drug treatment in those that survive. Moreover,
the drug treatment itself can lead to a range of long-term sequelae. Therefore, there is a crit-
ical need to identify new therapeutics for NB. Isoliquiritigenin (ISLQ) is a naturally-occurring,
dietary chalcone-type flavonoid with a range of biological effects that depend on the cell
type and context. ISLQ has potential as an anticancer agent. Here we show that ISLQ has
potent cytotoxic effects on SK-N-BE(2) and IMR-32 human NB cells, which carry amplifica-
tion of theMYCN gene, the main prognostic marker of poor survival in NB. ISLQ was found
to increase cellular reactive oxygen species (ROS). The cytotoxic effect of ISLQ was blocked
by small molecule inhibitors of oxidative stress-induced cell death, and by the antioxidant
N-acetyl-L-cysteine (NAC). Combined treatment of either SK-N-B-E(2) or IMR-32 cells with
ISLQ and the anticancer agent cisplatin resulted in loss of cell viability that was greater than
that induced by cisplatin alone. This study provides proof-of-principle that ISLQ is a potent
cytotoxin for MYCN-amplified human NB cells. This is an important first step in rationalizing
the further study of ISLQ as a potential adjunct therapy for high-risk NB.
Introduction
Neuroblastoma (NB) is the most common extracranial solid tumor of early childhood. It accounts for
approximately 8–10% of all childhood cancers and is responsible for 15% of childhood deaths as a result
of cancer [1]. NB arises from cells of sympathoadrenal lineage of the neural crest during development and
often presents as tumors in the neck, chest, abdomen, and pelvis [2–4]. Age, stage, and tumor phenotypes
are important prognostic factors inNB, and they guide treatment strategies [4]. In particular, amplification
of the MYCN oncogene [5] and/or inactivation of p53 [6] are associated with increased disease risk and
poorer outcomes.MYCN amplification is associated with rapid NB progression and poor prognosis [5,7],
while p53 stabilization has been linked to multi-drug resistance in NB [8]. For those diagnosed with low-
to intermediate-riskNB, the prognosis is relatively good, howevermany patients have high-riskmetastatic
disease that is resistant to multimodal therapy and that frequently relapses, resulting in a 5-year overall
survival rate of approximately 50% [2]. Those patients that survive often have long-term sequelae as a
result of toxicity associated with current chemotherapy regimens [9,10]. Therefore, there is a need for
novel therapies for NB that have fewer off-target effects.
The study of naturally occurring pharmacological agents to prevent, inhibit, and delay carcinogenesis is
a growing field of research, particularly in the area of cancer chemoprevention [11–13]. This strategy has
been derived from epidemiological studies which suggest that diets rich in fruits and vegetables can reduce
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the risk of cancer [14,15]. Flavonoids have received significant attention in this regard, not only as preventative strate-
gies, but also as potential chemotherapeutic agents [16,17]. In particular, isoliquiritigenin (ISLQ), a chalcone-derived
flavonoid naturally found in liquorice and shallots [18], has been investigated for its anticancer properties due to its
potent inhibition of cell proliferation and viability in a range of cancer cell types [19–29]. The anticancer effects of
ISLQ on NB are yet to be studied, however ISLQ has recently been found to induce cytotoxicity in the pheochromo-
cytoma (PC-12) cell line, which, like NB, has a neural crest origin [30], suggesting that ISLQ may have anticancer
effects in NB cells.
The anticancer properties of ISLQ have been attributed to its ability to inhibit cell cycle progression, and to induce
oxidative stress, apoptosis, autophagy, and/or necrosis. However, the precise mechanism of cytotoxicity is dependent
on cell type and usually involves a combination of cell death pathways [22,24,26,31]. Understanding the mechanisms
of cytotoxicity of ISLQ inNB cells will be important in determining its translational potential by improving knowledge
of its potential off-target effects, its efficacy in tumor subtypes, and its usefulness as a possible combination therapy
[32]. Here we sought to examine whether ISLQ treatment can exert anti-tumorigenic effects in MYCN-amplified NB
cells, as the first step in rationalizing the study of ISLQ as a potential therapeutic agent for high-risk pediatric NB.
Materials and methods
Cell culture
Cells were purchased from the American Type Culture Collection (through Sigma). SK-N-BE(2) cells were
maintained in Minimum Essential Medium (MEM) with 100 nM l-glutamine, 1% penicillin-streptomycin, 1%
non-essential amino acid solution (100×), 1% F-12 Hams with 15% FBS. IMR-32 cells were maintained in MEM
with 100 nM l-glutamine, 1% penicillin-streptomycin, 1% non-essential amino acid solution (100×) and 10% FBS.
All reagents were from Sigma. Cells were cultured in a humidified atmosphere containing 5% CO2 at 37◦C. Af-
ter 2 days in vitro, when the cells had optimally adhered, cultures were treated with 5–100 μM ISLQ or a vehicle
(equivalent percentage of DMSO; Sigma). For experiments involving inhibitors, cells were pre-treated with either:
50 μM Boc-D-FMK (Calbiochem), a cell-permeable, irreversible, broad-spectrum caspase inhibitor [37]; 10 μM
necrostatin-1 (Nec-1; Bio-techne), an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1
(RIPK1) that blocks non-apoptotic cell death via inhibition of a specific cellular pathway, necroptosis, which leads to
necrosis [39]; 3 μM IM-54 (Calbiochem), a small molecule inhibitor that selectively blocks oxidative stress-induced
necrotic cell death; or 100 μM Bax-inhibiting peptide V5 (‘Bax inhibitor’; Calbiochem), a membrane-permeable
pentapeptide inhibitor of Bax-mediated apoptosis [33]. As a control for the latter experiment, 100 μM of a corre-
sponding cell-permeable control for the Bax-Inhibiting Peptide, that does not suppress Bax-mediated apoptosis (‘Bax
control’; Calbiochem), was used. The antioxidant N-acetyl-l-cysteine (NAC; Sigma) was used at 1 mM. Cultures
were pre-treated with the inhibitors for 1 or 2 h before treatment with 25 μM of ISLQ for 24 h. In other experi-
ments, cultures were treated with 200 μM 6-hydroxydopamine (6-OHDA) for 4, 6, or 24 h or 10–100 μM cisplatin, a
chemotherapeutic drug [34] (AdooQ Bioscience), for 24 h.
Cell viability and death assays
For cell viability assays, cells were plated at a density of 1× 105 cells per well on 24-well plates. Phase contrast images
were captured using an Olympus IX71 inverted microscope fitted with an Olympus DP70 camera. At each experi-
mental end-point, MTT was added to the cells at a concentration of 1 mg/ml in culture medium for 4 h at 37◦C. The
culture medium was then removed and the formazon crystals were solubilized in DMSO. Absorbance was measured
at 540 nmwith a reference wavelength of 690 nm. Lactate dehydrogenase (LDH) activity wasmeasured in 50μl of cell
culture medium of each treatment group using an LDH Activity Assay Kit (Sigma), according to the manufacturer’s
instructions.
Oxidative stress assessment
To analyze oxidative stress, cultures were treated with 25 μM of ISLQ for 24 h, after which the cell-permeable dye
CellRox® (Thermo Fisher) was added at a final concentration of 5 μM, then cells were incubated for 30 min at 37◦C.
This dye exhibits bright green photostable fluorescence upon oxidation by reactive oxygen species (ROS) in living
cells. The cells were washed in sterilized 10 mM PBS and four microscopic fields were randomly captured per well
for each experiment, using an Olympus IX70 inverted microscope. The fluorescence intensity of individual cells was
measured using ImageJ.
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RNA isolation, cDNA synthesis, and real-time PCR
For analysis of gene expression, cultures were treated with 5 or 25 μM of ISLQ for 24 h. The medium was removed
and the cells washed in 10 mM PBS, before total RNA was extracted using TRIzol reagent as per the manufacturer’s
instructions (Invitrogen). The quantity and quality of the mRNAwas assessed using a NanoDrop 1000. Reverse tran-
scription was carried out using the high capacity cDNA Reverse Transcription Kit (Applied Biosystems) under the
following parameters: 25◦C for 10 min; 37◦C for 120 min; 85◦C for 5 min; 4◦C for 10 min. For real-time PCR, a
reaction mix consisting of 0.5 μl of 20X Gene Expression Assays (gapdh, bax, bcl2, caspase3; TaqMan® Applied
Biosystems), 0.5 μl of cDNA (20 ng/ml), 5 μl of TaqMan® Gene Expression Master Mix (Applied Biosystems) and 4
μl of RNase-free H2O (Applied Biosystems) was used. Each sample was run in duplicate under the following cycling
parameters: 50◦C for 2 min; 95◦C for 10 min; 40 repetitions of 95◦C for 15 s, and 60◦C for 1 min. Gene expression
levels were calculated using the 2−δCT method, normalizing to ACTB [35].
Immunocytochemistry
For immunocytochemistry, cells were fixed in 4%paraformaldehyde in 10mMPBS for 15min. The paraformaldehyde
was removed and the cells were washed three times for 5 min per wash in 10 mM PBS with 0.02% Triton (PBS-T).
Non-specific binding was blocked by incubation in 5% BSA in PBS-T for 1 h at room temperature. The blocking
solution was removed and primary antibody (Cell Signaling) to either cleaved caspase-3 or Bax, diluted 1:400 in 1%
BSA in PBS-T, was added to the culture wells, followed by incubation overnight at 4◦C. The primary antibody solution
was removed, cells were washed in PBS-T, then incubated inAlexa Fluor 488–conjugated secondary antibody (1:1000;
Invitrogen) diluted in 1%BSA in PBS-T, in the dark at room temperature for 2 h, then counterstained with DAPI. Five
microscopic fields were randomly captured per well per experiment using anOlympus IX71 invertedmicroscope, and
analyzed in a blinded fashion using ImageJ.
Statistical analysis
A one-way ANOVA with post-hoc Tukey’s or Dunnett’s test was performed to measure any significant differences
between groups. Results were expressed as mean +− S.E.M. and deemed significant when P<0.05.
Results
Effects of ISLQ treatment on cell viability in SK-N-BE(2) cultures
We first carried out a dose–response experiment on the effects of ISLQ treatment on cell viability in SK-N-BE(2) cul-
tures. This cell line isMYCN-amplified [36] and therefore a suitablemodel of aggressive NB, given thatMYCN ampli-
fication is the main prognostic marker of poor survival in NB [5]. Treatment with ISLQ at concentrations of 5 μMor
greater resulted in a dose-dependent decrease (P<0.01) in cell viability in SK-N-BE(2), as measured by MTT assays
(Figure 1A). This decrease in cell viability was not found in the corresponding control (DMSO vehicle only)-treated
cultures (Figure 1C). To confirm these findings, LDH activity was examined in culture medium from ISLQ-treated
SK-N-BE(2) cells. ISLQ treatment led to a significant increase (P<0.001) in LDH activity in SK-N-BE(2) cells, at con-
centrations of 50μMor greater (Figure 1B). There were no changes in LDH activity in DMSO vehicle-treated cultures
(data not shown). These results were confirmed by phase-contrast microscopy, which showed that ISLQ-treated cells
displayed morphological features consistent with cell death (Figure 1D). Collectively, these data demonstrate that
ISLQ treatment exerts concentration-dependent effects on viability in SK-N-BE(2) cells.
The cytotoxic effects of ISLQ on SK-N-BE(2) cells are Bax- and
caspase-independent
Since the biological mechanisms mediating the effects of ISLQ are varied and cell-type-specific [18], we sought to
determine the mode of cell death induced by ISLQ in SK-N-BE(2) cells. As ISLQ has been shown to increase the
expression of Bax, decrease the expression of Bcl-2, and lead to caspase-dependent cell death in human carcinoma
and hepatoma cells [37,38], we examined the involvement of Bax, Bcl-2, and caspases in ISLQ-induced cell death in
SK-N-BE(2) cells. First, SK-N-BE(2) cells were pre-treated with 100 μM of a cell-permeable peptide (‘Bax inhibitor’)
which is an effective inhibitor of Bax-mediated apoptosis, or with 100 μM of a control peptide (‘Bax control’), for 1
h prior to the addition of 25 μM ISLQ for 24 h. An MTT assay revealed that ISLQ treatment led to a significant de-
crease in cell viability in SK-N-BE(2) cells (P<0.001), which was not affected by pre-treatment with Bax inhibitor or
Bax control (Figure 2A). Second, SK-N-BE(2) cells were pre-treated with 50 μMof a broad-spectrum small molecule
caspase inhibitor (Boc-D-FMK) [39] for 2 h prior to the addition of 25 μM ISLQ for 24 h. AnMTT assay showed that
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Figure 1. ISLQ induces cell death in SK-N-BE(2) NB cells
Graphs of (A) MTT (n=9) and (B) LDH assays (n=9) on SK-N-BE(2) cells treated with ISLQ for 24 h. (C) Graph of an MTT assay (n=9)
on SK-N-BE(2) cells treated with vehicle (DMSO) for 24 h. (D) Representative phase-contrast photomicrographs of ISLQ-treated
cultures at 24 h. (**P<0.01, ***P<0.001 compared with control; ANOVA with post-hoc Tukey’s test). Scale bar = 100 μm. All data
are mean +− S.E.M.
ISLQ-induced cell death in SK-N-BE(2) cells was not prevented by caspase inhibition (Figure 2B). Furthermore, treat-
ment with 200 μM 6-OHDA, which has been reported to induce caspase-dependent cell death in this cell line [40],
resulted in a significant decrease (P<0.05) in cell viability, which was prevented by pre-treatment with Boc-D-FMK
(Figure 2B). Phase-contrast microscopy verified that pre-treatment with Boc-D-FMK did not prevent the cell death
induced by ISLQ (Figure 2C). This lack of rescue of ISLQ-induced cell death by inhibition of either Bax or caspase
was further supported by real-time PCR experiments, which showed that ISLQ treatment did not significantly alter
the levels of expression of bax (Figure 2D), bcl-2 (Figure 2E) or caspase-3 (Figure 2F) mRNA in SN-N-BE(2) cells.
In addition, and to further confirm these findings, we performed immunocytochemistry on SK-N-BE(2) cells us-
ing antibodies for Bax and for cleaved caspase-3. Following treatment of SK-N-BE(2) cultures for 4, 6, or 24 h with
200 μM 6-OHDA, significant numbers of cells stained positively for Bax and for cleaved caspase-3 (6 h time-point
shown in Figure 2G). In contrast, there were no Bax- or cleaved caspase-3-positive cells in cultures treated with 25
μM ISLQ (Figure 2G). Collectively, these data suggest that the cytotoxic effects of ISLQ in SK-N-BE(2) cells are Bax-
and caspase-independent, meaning that ISLQ induces cell death through other mechanisms in NB cells.
The cytotoxic effects of ISLQ on SK-N-BE(2) cells are mediated by
ROS-induced necrosis
Given that inhibition of either Bax or caspase did not block ISLQ-induced cell death, we next sought to deter-
mine if ISLQ induced cell death through necroptosis or necrosis. First, pre-treatment of SK-N-BE(2) cells for 2 h
with Nec-1, a cell-permeable, potent, and selective inhibitor of necroptosis [39], was used. MTT assays showed that
25 μM ISLQ led to a significant decrease in SK-N-BE(2) cell viability (P<0.001) at 24 h, which was partially pre-
vented by pre-treatment with 10 μMNec-1 (Figure 3A,D). Pre-treatment for 1 h with 3 μM IM-54, a small molecule
inhibitor that selectively blocks oxidative stress-induced necrotic cell death [41], fully blocked ISLQ-induced loss
of cell viability in SK-N-BE(2) cells (P<0.001) (Figure 3B,D). To further investigate the involvement of oxidative
stress in ISLQ-induced cell death, pre-treatment with the antioxidant NAC was used. An MTT assay showed that
pre-treatment with 1 mM NAC fully prevented (P<0.001) ISLQ-induced cell death in SK-N-BE(2) cells (Figure
4 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Inhibition of Bax or of caspase does not prevent ISLQ-induced death of SK-N-BE(2) cells
(A,B) Graphs of MTT assays and (C) representative phase-contrast photomicrographs of SK-N-BE(2) cells treated with 25 μM ISLQ
for 24 h with or without pre-treatment with (A) 100 μM of a Bax inhibitor peptide (‘Bax inh’) or of a control peptide (‘Bax cont’)
(n=6) or (B) 50 μM of Boc-D-FMK (n=12). Treatment with 200 μM 6-OHDA (green bars) for 24 h was used as a positive control.
Scale bar = 100 μm. (D–F) Graphs of real-time PCR data showing the relative expression of (D) bax mRNA, (E) bcl2mRNA, and (F)
caspase (casp)3 mRNA, normalized to that of β-actin (ACTB), in SK-N-BE(2) cells treated with non-cytotoxic (5 μM) and cytotoxic
(25 μM) concentrations of ISLQ for 24 h (n=4). (G) Representative photomicrographs of SK-N-BE(2) cells treated with 25 μM ISLQ
for 6 h, immunostained for cleaved caspase-3 or Bax. Treatment with 200 μM 6-OHDA was used as a positive control. (*P<0.05,
***P<0.001 compared with control; ANOVA with post-hoc Tukey’s test). Scale bar = 50 μm. All data are mean +− S.E.M.
3C,D). To confirm the role of oxidative stress in ISLQ-induced cell death, the CellRox® fluorogenic probe was used
to measure the cellular levels of ROS. SK-N-BE(2) cells were treated with ISLQ (25, 50, 100 μM) for 2, 4, and 6 h and
then cultures were loaded with the CellRox® fluorogenic probe and fluorescence intensity was measured as a read-
out of cellular ROS. ISLQ treatment for 24 h was found to increase ROS levels, to a similar extent to those in cultures
treated with a positive control (0.6 mMH2O2) (Figure 3E). The ISLQ-induced elevation of ROS levels was prevented
by pre-treatment for 1 h with IM-54 (Figure 3F,G). These data suggest that ISLQ-induced cell death is mediated by
ROS-mediated cell death.
Effects of ISLQ treatment on cell viability in IMR-32 cultures
We next performed experiments to investigate the cytotoxic effects of ISLQ treatment in IMR-32 NB cells, another
MYCN-amplified cell line. In agreement with our findings in SK-N-BE(2) cells, ISLQ treatment significantly reduced
(P<0.001) IMR-32 cell viability at concentrations of 5 μMor greater, as measured using at MTT assay (Figure 4A,D),
whereas there was no significant alteration in cell viability in cultures treated with DMSO vehicle (Figure 4C). These
results were confirmed using an LDH assay, which showed that ISLQ treatment led to a significant increase (P<0.05)
in LDH activity in IMR-32 cells, at concentrations of 5 μM or greater (Figure 4B). Moreover, in agreement with our
data on SK-N-BE(2) cells, pre-treatment with Nec-1 (Figure 5A,D), IM-54 (Figure 5B,D), or NAC (Figure 5C,D)
significantly prevented ISLQ-induced cell death in IMR-32 cells.
Effects of combined treatment with ISLQ and cisplatin in MYC-amplified
NB cells
To further explore the anticancer potential of ISLQ, we compared the cytotoxic effects of ISLQ treatment of both
SK-N-B-E(2) and IMR-32 cells with those of a commonly used anticancer drug, cisplatin. First, we conducted a
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. Inhibition of oxidative stress prevents ISLQ-induced death of SK-N-BE(2) cells
(A–C) Graphs of MTT assays and (D) representative photomicrographs of SK-N-BE(2) cells treated with 25 μM ISLQ for 24 h with
or without pre-treatment with (A) 10 μM Nec-1 necroptosis inhibitor) (n=9), (B) 3 μM IM-54 (inhibitor of oxidative stress-induced
necrosis) (n=12) or (C) 1 mM NAC (antioxidant) (n=9). (E,F) Graphs and (G) representative photomicrographs showing relative
fluorescence intensity of SK-N-BE(2) cells loaded with the CellRox fluorogenic probe that measures cellular oxidative stress (green).
(E) Cells were treated with 25 μM ISLQ for 2, 4, or 6 h, or with 0.6 mM H2O2 for 30 min (n=80). (F) Cells were pre-treated with 3 μM
IM-54 then cultured with or without 25 μM ISLQ for 24 h (n=240). (**P<0.01, ***P<0.001 compared with control or as indicated;
#P<0.05, ##P< 0.01, ###P<0.001 ISLQ compared with ISLQ + inhibitor; ANOVA with post-hoc Tukey’s test). Scale bar = 100 μm.
All data are mean +− S.E.M.
dose–response experiment using cisplatin alone and found that both cell lines were resistant to treatment with this
agent at concentrations less than 100 μM (Figure 6A,B), while 100 μM cisplatin induced a significant loss of cell
viability. Combined treatment of either SK-N-B-E(2) and IMR-32 cells with 10 μM ISLQ and 100 μM cisplatin for 24
h resulted in loss of cell viability that was significantly greater (P<0.001) than that induced by cisplatin alone (Figure
6C,D).
Discussion
ISLQ is a naturally-occurring bioactive compound isolated from the roots of plants belonging to the liquorice family,
with a range of biological effects that depend on the cell type and context [18]. Although the effects of ISLQ in a range
of different cancers have been reported [23,26,42–48], to our knowledge there has been no study that has investigated
the potential of ISLQ as a cytotoxic agent for NB. This is particularly important given the poor prognosis of NB, and
the fact that many NB relapses are drug resistant, while current therapies can have a range of long-term sequelae
[9,10]. Thus, the identification of new and/or adjunct therapeutic approaches for NB is essential. To address this, we
6 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. ISLQ induces cell death in IMR-32 NB cells
Graphs of (A) MTT (n=9) and (B) LDH assays (n=9) on IMR-32 cells treated with ISLQ for 24 h. (C) Graph of an MTT assay on
IMR-32 cells treated with vehicle (DMSO) for 24 h (n=9). (D) Representative phase-contrast photomicrographs of ISLQ-treated
IMR-32 cells at 24 h. (*P<0.05, ***P<0.001 compared with control; ANOVA with post-hoc Tukey’s test). Scale bar = 100 μm. All
data are mean +− S.E.M.
Figure 5. Inhibition of oxidative stress prevents ISLQ-induced cell death of IMR-32 cells
(A–C) Graphs of MTT assay and (D) representative photomicrographs of IMR-32 cells treated with 25 μM ISLQ for 24 h with or
without pre-treatment with (A) 10 μM Nec-1 (n=9), (B) 3 μM IM-54 (n=12), or (C) 1 mM of NAC (n=9). (***P<0.001 compared with
control; ###P<0.001 ISLQ compared with ISLQ + inhibitor; ANOVA with post-hoc Tukey’s test). Scale bar = 100 μm. All data are
mean +− S.E.M.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 6. Effects of combined treatment with ISLQ and cisplatin on NB cells
(A,B) Graphs of MTT assays on (A) SK-N-BE(2) cells (n=11) and (B) IMR-32 cells (n=10) treated with cisplatin (CP) for 24 h. (C,D)
Graphs of MTT assays on (C) SK-N-BE(2) cells (n=6) and (D) IMR-32 cells (n=6) treated with 10 μM ISLQ for 24 h with or without
100 μMCP (concentrations shown in parentheses). (*P<0.05, **P<0.01, ***P<0.001 compared with control; ###P<0.001 compared
with both ISLQ and CP in (C), ##P<0.01 compared with CP in (D); ANOVA with post-hoc Tukey’s test). Scale bar = 100 μm. All data
are mean +− S.E.M.
used SK-N-BE(2) (p53 mutant) and IMR-32 cells to demonstrate that ISLQ exerts potent cytotoxic effects in both of
these MYCN-amplified NB cell lines. SK-N-BE(2) cells, due to MYCN amplification and mutant p53, become highly
resistant to apoptosis. One of the most important functions of p53 is its ability to activate apoptosis, and disruption of
this process can promote tumor progression and chemoresistance [49]. We found that the cytotoxic effects of ISLQ in
NB cells were mediated through oxidative stress-induced cell death, as evidenced by increases in cellular ROS levels,
rather than through apoptosis or necroptosis. As a result, these data provide proof-of-principle that further study of
ISLQ may be useful in developing new therapeutic approaches to high-risk NB.
In the present study, we found that ISLQ decreased viability of SK-N-BE(2) and IMR-32 cells when applied in the
lower micromolar range, at concentrations of 5 μM or greater, for 24 h. This is similar to data reported in a recent
study on the PC-12 neuronal cell line, which used a similar approach and found that ISLQ had a cytotoxic effect on
these cells, with an IC50 of 17.8 μM [30]. Similarly, another study reported a cytotoxic effect of ISLQ on U87 glioma
cells, with an IC50 of 6.3 μM, while it displayed minimal toxicity against normal brain cells [50]. A cytotoxic effect of
ISLQ on SH-SY5Y cells has also been reported in a published abstract, which stated that treatment with 10–200 μM
ISLQ for 24 h decreased cell viability [51]. This is fully consistent with our data on IMR-32 and SK-N-BE(2) NB cells,
where ISLQ treatment for 24 h significantly reduced cell viability at concentrations of 5 μM or greater.
The precise mechanism of ISLQ-induced cytotoxicity in cancer cells is dependent on cell type and usually involves
a combination of cell death pathways, including oxidative stress, apoptosis, autophagy, and/or necrosis [22,24,26,31].
Given that previous studies had reported that ISLQ treatment of human bladder cancer T24 cells led to the increase in
the expression of bax and caspase 3 transcripts [26], we hypothesized that ISLQmay have a similar effect in NB cells.
8 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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However, we found no change in the expression of these genes in SK-N-BE(2) cells after treatment with cytotoxic
concentrations of ISLQ. In agreement with this, a published abstract reported no significant changes in caspase3/7
activation in SH-SY5Y cells after treatment with 10–200 μM ISLQ for 24 h [51]. This is fully consistent with our
real-time PCR and immunocytochemistry results in SK-N-BE(2) cells, and is also further supported by our finding
that treatment with a broad-spectrum caspase inhibitor or with a Bax inhibitor did not prevent ISLQ-induced cell
death. Also in support of this, a previous report demonstrated that ISLQ induced cell death and caspase activation
in U87 glioma cells [27]. However, in that study, while treatment of U87 glioma cells with the pan-caspase inhibitor
Z-VAD-FMK blocked ISLQ-induced caspase activation, it did not eliminate ISLQ-induced cell death [27]. In agree-
ment, we also report that ISLQ-induced cell death was not prevented by a broad-spectrum caspase inhibitor or by a
Bax inhibitor, suggesting that, at least in SK-N-BE(2) cells, ISLQ-induced cell death is independent of both Bax and
caspase.
Necrosis has been considered as an accidental and non-regulated cell death process. However, recent studies have
shed light on a new concept of regulated necrosis called RIPK-dependent necrosis (or necroptosis). The most promi-
nent characteristics of this type of cell death are an involvement of RIPK1 kinase activation (which can be assessed by
monitoring RIPK1 phosphorylation) and suppression by several RIPK1 inhibitors, including Nec-1 [52]. Currently,
the primary method for confirming necroptosis involves detection of the key molecules that control this process (i.e.
RIP1, RIP3, andMLKL) [53,54]. RIP1/3 has been found to promote anti-metastatic outcomes by regulating oxidative
stress to kill metastatic tumor cells [55,56]. In the present study, we found that ISLQ-induced death in SK-N-BE(2)
and IMR-32 cells was partially prevented by pre-treatment with nec-1, an inhibitor of RIPK1. The fact that the inhi-
bition was partial may be explained by the finding that some necrosis inducers can act by directly activating RIPK3 or
MLKL, by-passing RIPK1 activation [57]. In addition, we found that cell death induced by ISLQ was fully blocked by
pre-treatmentwith IM-54, an inhibitor of oxidative stress-induced cell death [41]. This is supported by the demonstra-
tion that ISLQ treatment increased cellular ROS, and that the antioxidant NAC prevented ISLQ-induced cell death, in
both cell lines tested in our study. A high concentration (1 mM) of NAC was used, due to the need to compensate for
depletion of the cellular antioxidant, glutathione [58]. An involvement of ROS in necroptosis has been reported [59].
Moreover, several studies have shown that necroptosis is accompanied by increased ROS production in human [60]
and murine [61] cancer cell types. This supports elevation of oxidative stress as a potential mechanism underlying
cell death triggered by necroptosis. These findings are supported by studies showing that ISLQ treatment induced
redox imbalance and increased oxidative stress in HepG2 hepatocellular carcinoma cells [62] and in HeLa cells [63].
Moreover, dietary flavonoids, including ISLQ, have been shown to be metabolized to pro-oxidant radicals [64]. Sim-
ilar findings have been reported in neuronal-like cells; for example, PC-12 cells treated with 10 or 20 μM ISLQ for 24
h display increases in intracellular ROS [30]. This is very similar to the present study, in which SK-N-BE(2) treated
with 25 μM ISLQ for 24 h showed an increase in intracellular ROS. This elevation of ROS levels in SK-N-BE(2) cells
peaked quite early after ISLQ treatment, that is, between 2 and 4 h. This suggests that oxidative stress plays a sub-
stantial role in the initiation of cell death induced by ISLQ. Elevated rates of ROS have been detected in almost all
cancers, where they promotemany aspects of tumor development and progression. However, tumor cells also express
increased levels of antioxidant proteins which can detoxify ROS, suggesting that a delicate balance of intracellular
ROS levels is required for cancer cell function. The dependence of tumor cells and cancer stem cells on their an-
tioxidant capacity makes them vulnerable to agents that dampen antioxidant systems. There is a realistic prospect
for treatments aimed at dramatically increasing intracellular ROS to kill cancer cells by decreasing their antioxidant
capacity [65,66]. The advantage of such a strategy is that normal cells are not significantly affected, since they have
lower basal ROS levels and therefore are less dependent on antioxidants. However, it is worth noting that there are
numerous instances where antioxidant effects of ISLQ have been reported. For example, treatment of human arterial
smooth muscle cells with 10 μM of ISLQ, which is similar to the concentration used in the present study, has been
reported to reduce ROS levels, despite the fact that it also significantly decreased cell viability [67]. Additionally, a
recent study that performed microarray analysis on ISLQ-treated PC-3 prostate cancer cells reported a significant
enrichment of differentially-expressed genes involved in the gene ontology category ‘response to oxidative stress’
[42]. These data suggest that ISLQ can have both pro- and anti-oxidant activities, depending on the cell type. In the
present study, we show that ISLQ treatment increases cellular ROS, and that this is involved inmediating the cytotoxic
effects of ISLQ on human NB cells. It is also worth noting that a recent study identified ISLQ as a natural mimetic of
rapamycin [68], which is an FDA-approved mTOR inhibitor that has anti-carcinogenic effects in NB cells [69]. Treat-
ment of NB cells with rapamycin for 24 h has been shown to increase cellular levels of ROS [70], which is consistent
with the increases in cellular oxidative stress in MYCN-amplified SK-N-BE(2) cells induced by ISLQ treatment for
24 h, found in our study. It is also worth noting that MYCN amplification has recently been shown to increase ROS,
and to confer sensitivity to an ROS-augmenting agent in NB cells [71]. Our present study is consistent with this, as it
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found that ISLQ had cytotoxic effects at concentrations of 5 μMor greater, onMYCN-IMR-32 andMYCN-amplified
SK-N-BE(2) cells. This suggests that MCYN-amplified NB may be particularly sensitive to ISLQ-induced ROS.
The up-regulation of endogenous antioxidant systems by cancer cells as an adaptation to situations of oxidative
stress can limit the effectiveness of many chemotherapy agents [72]. Furthermore, ROS generated by the adminis-
tration of such agents can lead to the damage of healthy tissues, resulting in numerous deleterious side-effects. For
example, oxidative stress mechanisms are known to be involved in the cardiotoxicity mediated by anthracycline [73],
and in the nephrotoxicity triggered by platinum compounds [74]; these are long-term serious sequelae associated
with the use of these commonly-used chemotherapy agents. Pediatric NB has been reported to be resistant to the
chemotherapeutic agent, cisplatin [75]. In the present study, we found that both SK-N-BE(2) and IMR-32 NB cells
lines were resistant to treatment with cisplatin at concentrations less than 100μM. Furthermore, we report synergistic
effects of combined treatment with ISLQ and cisplatin, at relatively low doses. The use of such low doses in combi-
nation could minimize the advent of deleterious side-effects on other healthy tissues, which may occur following
treatment with higher doses of cisplatin.
The present study has shown potent cytotoxic effects of the dietary flavonoid, ISLQ, on MYCN-amplified
SK-N-BE(2) and IMR-32 NB cell lines. One limitation of the current study that will be important to address in future
investigations is the need to identify the proteins and molecular pathways that mediate the link between ISLQ treat-
ment and oxidative stress. Given the aggressive nature of MYCN-amplified NB, and the fact that NB relapses can be
refractory to treatment, these data are an important first step in rationalizing the further study of ISLQ as a potential
therapeutic agent for high-risk pediatric NB. Additionally, the evidence to support combination therapy of ISLQwith
cisplatin is an important finding, that may allow lower doses of these agents to be used to reduce the incidence of
serious long-term sequalae.
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